Neuroreceptor mechanisms of aggression and its treatment

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 4, 2003, Pages 26-35

  Swann, Alan C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIAZEPAM; DILATIN; DOPAMINE; EXCITATORY AMINO ACID; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; LAMOTRIGINE; LEUPRORELIN; LITHIUM; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NICOTINIC RECEPTOR; OLANZAPINE; PHENYTOIN; PINDOLOL; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEQOQUEL; SEROTONIN 1A AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AGGRESSION; AKATHISIA; ANGER; ARTICLE; BEHAVIOR THERAPY; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYMPTOM; GABAERGIC TRANSMISSION; HUMAN; HYPERTHERMIA; IMPULSIVENESS; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMISSION; PRIORITY JOURNAL; RELAPSE; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; STRESS; SUBSTANCE ABUSE;

AGGRESSION; ANDROGEN ANTAGONISTS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; IMPULSIVE BEHAVIOR; INTERPERSONAL RELATIONS; LITHIUM; PSYCHOTHERAPY; RECEPTORS, SENSORY; SEROTONIN AGENTS;

EID: 0037259609     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (159)

1. Barratt ES, Stanford MS, Felthous AR, et al. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 1997;17:341-349
2. Buchanan A, Reed A, Wessely S, et al. Acting on delusions, 2: the phenomenological correlates of acting on delusions. Br J Psychiatry 1993;163:77-81
3. Moeller FG, Barratt ES, Dougherty DM, et al. Psychiatric aspects of impulsivity. Am J Psychiatry 2001;158:1783-1793
4. Bechara A, Damasio H, Tranel D, et al. Deciding advantageously before knowing the advantageous strategy [see comments]. Science 1997;275:1293-1295
5. Brown GL, Goodwin FK, Ballenger JC, et al. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979;1:131-139
6. Brown GL, Linnoila MI. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J Clin Psychiatry 1990;51(4, suppl):31-41; discussion
7. Bizot JC, Le Bihan C, Puech AJ, et al. Serotonin and tolerance to delay of reward in rats. Psychopharmacology (Berl) 1999;146:400-412
8. Harrison AA, Everitt BJ, Robbins TW. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl) 1997;133:329-342
9. Mobini S, Chiang TJ, Al Ruwaitea AS, et al. Effect of central 5-hydroxytryptamine depletion on inter-temporal choice: a quantitative analysis. Psychopharmacology (Berl) 2000;149:313-318
10. Puumala T, Sirvio J. Changes in activities of dopamine and scrotonin systems in the frontal cortex underlie poor choice accuracy and impulsivity of rats in an attention task. Neuroscience 1998;83:489-499
11. Brunner D, Hen R. Insights into the neurobiology of impulsive behavior from serotonin receptor knockout mice. Ann N Y Acad Sci 1997;836:81-105
12. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry 1989;155(suppl 8):52-62
13. Linnoila M, Virkkunen M, Scheinin M, et al. Low cerebrospinal fluid 5HIAA differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983;32:2609-2614
14. Cremniter D, Jamain S, Kollenbach K, et al. CSF 5-HIAA levels are lower in impulsive as compared to nonimpulsive violent suicide attempters and control subjects. Biol Psychiatry 1999;45:1572-1579
15. Asberg M. Neurotransmitters and suicidal behavior: the evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 1997;836:158-181
16. Nordstrom P, Samuelsson M, Asberg M, et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav 1994;24:1-9
17. Nurnberger JI Jr, Berrettini WH, Simmons-Alling S, et al. Blunted ACTH and cortisol response to afternoon tryptophan infusion in euthymic bipolar patients. Psychiatry Res 1990;31:57-67
18. Roy A, De Jong J, Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients: a five-year follow-up study. Arch Gen Psychiatry 1989;46:609-612
19. Bjork JM, Dougherty DM, Moeller FG, et al. Differential behavioral effects of plasma tryptophan depletion and loading in aggressive and non-aggressive men. Neuropsychopharmacology 2000;22:357-369
20. Cole BJ, Robbins TW. Amphetamine impairs the discriminative performance of rats with dorsal noradrenergic bundle lesions on a 5-choice serial reaction time task: new evidence for central dopaminergic-noradrenergic interactions. Psychopharmacology (Berl) 1987;91:458-466
21. Evenden J, Meyerson B. The behavior of spontaneously hypertensive and Wistar Kyoto rats under a paced fixed consecutive number schedule of reinforcement. Pharmacol Biochem Behav 1999;63:71-82
22. Evenden JL, Ryan CN. The pharmacology of impulsive behaviour in rats: the effects of drugs on response choice with varying delays of reinforcement. Psychopharmacology (Berl) 1996;128:161-170
23. Evenden JL. The pharmacology of impulsive behaviour in rats, 3: the effects of amphetamine, haloperidol, imipramine, chlordiazepoxide and ethanol on a paced fixed consecutive number schedule. Psychopharmacology (Berl) 1998;138:295-304
24. Evenden JL. The pharmacology of impulsive behaviour in rats, 2: the effects of amphetamine, haloperidol, imipramine, chlordiazepoxide and other drugs on fixed consecutive number schedules (FCN 8 and FCN 32). Psychopharmacology (Berl) 1998;138:283-294
25. Sostek AJ, Buchsbaum MS, Rapoport JL. Effects of amphetamine on vigilance performance in normal and hyperactive children. J Abnorm Child Psychol 1980;8:491-500
26. Arque JM, Unzeta M, Torrubia R. Neurotransmitter systems and personality measurements: a study in psychosomatic patients and healthy subjects. Neuropsychobiology 1988;19:149-157
27. Klinteberg B, Levander SE, Oreland L, et al. Neuropsychological correlates of platelet monoamine oxidase (MAO) activity in female and male subjects. Biol Psychol 1987;24:237-252
28. Verkes RJ, Van der Mast RC, Kerkhof AJ, et al. Platelet serotonin, monoamine oxidase activity, and [3H]paroxetine binding related to impulsive suicide attempts and borderline personality disorder. Biol Psychiatry 1998;43:740-746
29. Zuckerman M. P-impulsive sensation seeking and its behavioral, psychophysiological and biochemical correlates. Neuropsychobiology 1993;28:30-36
30. Bergh C, Eklund T, Sodersten P, et al. Altered dopamine function in pathological gambling. Psychol Med 1997;27:473-475
31. King RJ, Mefford IN, Wang C, et al. CSF dopamine levels correlate with extraversion in depressed patients. Psychiatry Res 1986;19:305-310
32. Comings DE, Johnson JP, Gonzalez NS, et al. Association between the adrenergic alpha 2A receptor gene (ADRA2A) and measures of irritability, hostility, impulsivity and memory in normal subjects. Psychiatr Genet 2000;10:39-42
33. Gerra G, Avanzini P, Zaimovic A, et al. Neurotransmitters, neuroendocrine correlates of sensation-seeking temperament in normal humans. Neuropsychobiology 1999;39:207-213
34. Roy A, Adinoff B, Roehrich L, et al. Pathological gambling: a psychobiological study. Arch Gen Psychiatry 1988;45:369-373
35. Roy A, De Jong J, Linnoila M. Extraversion in pathological gamblers: Correlates with indexes of noradrenergic function. Arch Gen Psychiatry 1989;46:679-681
36. Swann AC, Koslow SH, Katz MM, et al. Lithium carbonate treatment of mania: cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Arch Gen Psychiatry 1987;44:345-354
37. Smiley JF. Monoamines and acetylcholine in primate cerebral cortex: what anatomy tells us about function. Rev Bras Biol 1996;56(Su 1 Pt 1):153-164
38. Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 1997;11:151-162
39. Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000;23:11-25
40. van Praag HM, Asnis GM, Kahn RS, et al. Monoamines and abnormal behavior: a multi-aminergic perspective. Br J Psychiatry 1990;157:723-734
41. Robbins TW. Arousal systems and attentional processes. Biol Psychol 1997;45:57-71
42. Soltis RP, Cook JC, Gregg AE, et al. Interaction of GABA and excitatory amino acids in the basolateral amygdala: role in cardiovascular regulation. J Neurosci 1997;17:9367-9374
43. Lang A, Harro J, Soosaar A, et al. Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn Schmiedebergs Arch Pharmacol 1995;351:363-370
44. Depaulis A, Vergnes M. GABAergic modulation of mouse-killing in the rat. Psychopharmacology (Berl) 1984;83:367-372
45. Molina V, Ciesielski L, Gobaille S, et al. Effects of the potentiation of the GABAergic neurotransmission in the olfactory bulbs on mouse-killing behavior. Pharmacol Biochem Behav 1986;24:657-664
46. Puglisi-Allegra S, Simler S, Kempf E, et al. Involvement of the GABAergic system on shock-induced aggressive behavior in two strains of mice. Pharmacol Biochem Behav 1981;14(suppl 1):13-18
47. Puglisi-Allegra S, Mandel P. Effects of sodium n-dipropylacetate, muscimol hydrobromide and (R,S) nipecotic acid amide on isolation-induced aggressive behavior in mice. Psychopharmacology (Berl) 1980;70:287-290
48. Barratt ES, Slaughter L. Defining, measuring, and predicting impulsive aggression: a heuristic model. Behav Sci Law 1998;16:285-302
49. Barratt ES. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep 1965;16:547-554
50. Barratt ES. Psychophysiological correlates of classical differential eyelid conditioning among subjects selected on the basis of impulsiveness and anxiety. Biol Psychiatry 1971;3:339-346
51. Katz MM, Wetzler S, Cloitre M, et al. Expressive characteristics of anxiety in depressed men and women. J Affect Disord 1993;28:267-277
52. Korn ML, Plutchik R, van Praag HM. Panic-associated suicidal and aggressive ideation and behavior. J Psychiatr Res 1997;31:481-487
53. Benes FM. The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. J Psychiatr Res 1997;31:257-275
54. Yoshida M, Yokoo H, Nakahara K, et al. Local muscimol disinhibits mesolimbic dopaminergic activity as examined by brain microdialysis and Fos immunohistochemistry. Brain Res 1997;767:356-360
55. Blondel A, Sanger DJ, Moser PC. Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology (Berl) 2000;149:293-305
56. Berntson GG, Beattie MS, Walker JM. Effects of nicotinic and muscarinic compounds on biting attack in the cat. Pharmacol Biochem Behav 1976;5:235-239
57. Driscoll P, Baettig K. Selective inhibition by nicotine of shock-induced fighting in the rat. Pharmacol Biochem Behav 1981;14:175-179
58. Waldbillig RJ. Suppressive effects of intraperitoneal and intraventricular injections of nicotine on muricide and shock-induced attack on conspecifics. Pharmacol Biochem Behav 1980;12:619-623
59. Seth P, Cheeta S, Tucci S, et al. Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav 2002;71:795-805
60. Cherek DR. Effects of cigarette smoking on human aggressive behavior. Prog Clin Biol Res 1984;169:333-344
61. Cherek DR. Effects of smoking different doses of nicotine on human aggressive behavior. Psychopharmacology (Berl) 1981;75:339-345
62. Cherek DR, Bennett RH, Grabowski J. Human aggressive responding during acute tobacco abstinence: effects of nicotine and placebo gum. Psychopharmacology (Berl) 1991;104:317-322
63. Parrott DJ, Zeichner A. Effects of nicotine deprivation and irritability on physical aggression in male smokers. Psychol Addict Behav 2001;15:133-139
64. Yoshimura H, Ueki S. Biochemical correlates in mouse-killing behavior of the rat: prolonged isolation and brain cholinergic function. Pharmacol Biochem Behav 1977;6:193-196
65. Yoburn BC, Glusman M. The effects of intrahypothalamic hemicholinium-3 on muricide, irritability and feeding. Pharmacol Biochem Behav 1984;20:829-833
66. Pucilowski O, Eichelman B, Overstreet DH, et al. Enhanced affective aggression in genetically bred hypercholinergic rats. Neuropsychobiology 1990;24:37-41
67. Banks T, Dabbs JM Jr. Salivary testosterone and cortisol in a delinquent and violent urban subculture. J Soc Psychol 1996;136:49-56
68. Bergman B, Brismar B. Hormone levels and personality traits in abusive and suicidal male alcoholics. Alcohol Clin Exp Res 1994;18:311-316
69. Gerra G, Zaimovic A, Avanzini P, et al. Neurotransmitter-neuroendocrine responses to experimentally induced aggression in humans: influence of personality variable. Psychiatry Res 1997;66:33-43
70. Higley JD, Mehlman PT, Poland RE, et al. CSF testosterone and 5-HIAA correlate with different types of aggressive behaviors. Biol Psychiatry 1996;40:1067-1082
71. Bjork JM, Moeller FG, Dougherty DM, et al. Endogenous plasma testosterone levels and commission errors in women: a preliminary report. Physiol Behav 2001;73:217-221
72. Kouri EM, Lukas SE, Pope HG Jr, et al. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend 1995;40:73-79
73. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000;57:133-140
74. Dougherty DM, Bjork JM, Huckabee HC, et al. Laboratory measures of aggression and impulsivity in women with borderline personality disorder. Psychiatry Res 1999;85:315-326
75. Cherek DR, Moeller FG, Dougherty DM, et al. Studies of violent and nonviolent male parolees, 2: laboratory and psychometric measurements of impulsivity. Biol Psychiatry 1997;41:523-529
76. Cherek DR, Moeller FG, Schnapp W, et al. Studies of violent and non-violent male parolees, 1: laboratory and psychometric measurements of aggression. Biol Psychiatry 1997;41:514-522
77. Cascella NG, Nagoshi CT, Muntaner C, et al. Impulsiveness and subjective effects of intravenous cocaine administration in the laboratory. J Subst Abuse 1994;6:355-366
78. Moeller FG, Dougherty DM, Lane SD, et al. Antisocial personality disorder and alcohol-induced aggression. Alcohol Clin Exp Res 1998;22:1989-1902
79. Moeller FG, Dougherty DM, Rustin T, et al. Antisocial personality disorder and aggression in recently abstinent cocaine dependent subjects. Drug Alcohol Depend 1997;44:175-182
80. Moeller FG, Dougherty D, Barratt E, et al. Increased impulsivity in cocaine dependent subjects independent of antisocial personality disorder and aggression. Drug Alcohol Depend 2002;68:105-111
81. Dougherty DM, Steinberg JL, Wassef AA, et al. Immediate versus delayed visual memory task performance among schizophrenic patients and normal control subjects. Psychiatry Res 1998;79:255-265
82. Cheung P, Schweitzer I, Crowley K, et al. Aggressive behaviour in schizophrenia: the role of psychopathology. Aust N Z J Psychiatry 1997;31:62-67
83. Cheung P, Schweitzer I, Crowley KC, et al. Aggressive behaviour and extrapyramidal side effects of neuroleptics in schizophrenia. Int Clin Psychopharmacol 1996;11:237-240
84. Nair CJ, Josiassen RC, Abraham G, et al. Does akathisia influence psychopathology in psychotic patients treated with clozapine? Biol Psychiatry 1999;45:1376-1383
85. Chow LY, Chung D, Leung V, et al. Suicide attempt due to metoclopramide-induced akathisia. Int J Clin Pract 1997;51:330-331
86. de Leon J, Diaz FJ, Rogers T, et al. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 2002;56:47-54
87. Diwan A, Castine M, Pomerleau CS, et al. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 1998;33:113-118
88. Daneluzzo E, Arduini L, Rinaldi O, et al. PANSS factors and scores in schizophrenic and bipolar disorders during an index acute episode: a further analysis of the cognitive component. Schizophr Res 2002;56:129-136
89. Leonard S, Adler LE, Benhammou K, et al. Smoking and mental illness. Pharmacol Biochem Behav 2001;70:561-570
90. Levin ED, Wilson WH, Rose JE, et al. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996;15:429-436
91. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute; 1996
92. Swann AC, Anderson JC, Dougherty DM, et al. Measurement of interepisode impulsivity in bipolar disorder. Psychiatry Res 2001;101:195-197
93. Swann AC, Pazzaglia P, Nicholls A, et al. Bipolar disorder and impulsiv]ity: relationship to the manic state. J Affect Disord. In press
94. Gonzalez-Pinto A, Gutierrez M, Ezcurra J, et al. Tobacco smoking and bipolar disorder. J Clin Psychiatry 1998;59:225-228
95. Benazzi F. Severe mania following abrupt nicotine withdrawal [letter]. Am J Psychiatry 1989;146:1641
96. McElroy SL, Pope HG Jr, Keck PE Jr, et al. Are impulse-control disorders related to bipolar disorder? Compr Psychiatry 1996;37:229-240
97. Barlow K, Grenyer B, Ilkiw-Lavalle O. Prevalence and precipitants of aggression in psychiatric inpatient units. Aust N Z J Psychiatry 2000;34:967-974
98. Gut-Fayand A, Dervaux A, Olie JP, et al. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Res 2001;102:65-72
99. Grof P, Grof E. Varieties of lithium benefit. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:689-696
100. Sheard M. Effect of lithium on human aggression. Nature 1971;230:113-114
101. Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984;41:650-656
102. Marini JL, Sheard MH, Kosten T. Study of the role of serotonin in lithium action using shock-elicited fighting. Community Psychopharmacol 1979;3:225-233
103. Sheard MH, Marini JL, Bridges CI, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976;133:1409-1413
104. Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995;91:348-351
105. Chatham-Showalter PE. Carbamazepine for combativeness in acute traumatic brain injury. J Neuropsychiatry Clin Neurosci 1996;8:96-99
106. Azoavi P, Jokic C, Attal N, et al. Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: results of an open trial. Brain Inj 1999;13:797-804
107. Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996;35:480-490
108. Leucht S, McGrath J, White P, et al. Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane Review). Cochrane Database Syst Rev 2002; CD001258
109. Wulsin L, Bachop M, Hoffman D. Group therapy in manic-depressive illness. Am J Psychother 1988;42:263-271
110. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001;62:199-203
111. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a doubleblind placebo-controlled pilot study. J Clin Psychiatry 2002;63:442-446
112. Donovan SJ, Susser ES, Nunes EV, et al. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 1997;58:12-15
113. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000;157:818-820
114. Lindenmayer J-P, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000;61:123-128
115. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998;59:676-680
116. Vitiello B, Behar D, Hunt J, et al. Subtyping aggression in children and adolescents. J Neuropsychiatry Clin Neurosci 1990;2:189-192
117. Kruger S, Braunig P. Intravenous valproic acid in the treatment of severe catatonia [letter]. J Neuropsychiatry Clin Neurosci 2001;13:303-304
118. Allen MH, Currier GW, Hughes DH, et al. The Expert Consensus Guideline Series: Treatment of Behavioral Emergencies. Postgrad Med 2001;1-88
119. Beck NC, Greenfield SR, Gotham H, et al. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. J Am Acad Psychiatry Law 1997;25:461-468
120. Chengappa KN, Levine J, Ulrich R, et al. Impact of risperidone on seclusion and restraint at a state psychiatric hospital. Can J Psychiatry 2000;45:827-832
121. Hector RI. The use of clozapine in the treatment of aggressive schizophrenia. Can J Psychiatry 1998;43:466-472
122. Chengappa KN, Vasile J, Levine J, et al. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophr Res 2002;53:1-6
123. Garmendia L, Sanchez JR, Azpiroz A, et al. Clozapine: strong antiaggressive effects with minimal motor impairment. Physiol Behav 1992;51:51-54
124. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-611
125. Haspel T. Beta-blockers and the treatment of aggression. Harv Rev Psychiatry 1995;2:274-281
126. Kaplan SL, Busner J, Kupietz S, et al. Effects of methylphenidate on adolescents with aggressive conduct disorder and ADHD: a preliminary report. J Am Acad Child Adolesc Psychiatry 1990;29:719-723
127. Casat CD, Pearson DA, Van Davelaar MJ, et al. Methylphenidate effects on a laboratory aggression measure in children with ADHD. Psychopharmacol Bull 1995;31:353-356
128. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression, 1: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 2002;41:253-261
129. Davis WM. Psychopharmacologic violence associated with cocaine abuse: kindling of a limbic dyscontrol syndrome? Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1273-1300
130. Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication [letter]. Am J Psychiatry 1991;148:1099-1100
131. Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989;146:1598-1601
132. Hirose S, Ashby CR. Immediate effect of intravenous diazepam in neuroleptic-induced acute akathisia: an open-label study. J Clin Psychiatry 2002;63:524-527
133. Amadeo M. Antiandrogen treatment of aggressivity in men suffering from dementia. J Geriatr Psychiatry Neurol 1996;9:142-145
134. Kyomen HH, Satlin A, Hennen J, et al. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial. Am J Geriatr Psychiatry 1999;7:339-348
135. Cook EH Jr, Leventhal BL. Down's syndrome with mania. Br J Psychiatry 1987;150:249-250
136. Britton KR. Medroxyprogesterone in the treatment of aggressive hypersexual behavior in traumatic brain injury. Brain Inj 1998;12:703-707
137. Bahrke MS, Yesalis CE III, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids: an update. Sports Med 1996;22:367-390
138. Rodriguez MM, Grossberg GT. Estrogen as a psychotherapeutic agent. Clin Geriatr Med 1998;14:177-189
139. Wassef AA, Dott SG, Harris A, et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999;19:222-232
140. Soderstrom H, Blennow K, Manhem A, et al. CSF studies in violent offenders, 1: 5-HIAA as a negative and HVA as a positive predictor of psychopathy. J Neural Transm 2001;108:869-878
141. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Arch Gen Psychiatry 1979;36:327-333
142. Charney DS, Kales A, Soldatos CR, et al. Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment. Br J Psychiatry 1979;135:418-424
143. Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999;19:310-315
144. Saba G, Dumortier G, Kalalou K, et al. Lamotrigine-clozapine combination in refractory schizophrenia: three cases [letter]. J Neuropsychiatry Clin Neurosci 2002;14:86
145. Drapalski AL, Rosse RB, Peebles RR, et al. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001;24:290-294
146. Winterer G, Hermann WM. Valproate and the symptomatic treatment of schizophrenia spectrum patients. Dig Dis Sci 2000;33:182-188
147. Bogan AM, Brown ES, Suppes T. Efficacy of divalproex therapy for schizoaffective disorder. J Clin Psychopharmacol 2000;20:520-522
148. Wassef AA, Hafiz NG, Hampton D, et al. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol 2001;21:21-26
149. Wassef AA, Dott SG, Harris A, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000;20:357-361
150. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 2001;7:283-304
151. Allan ER, Alpert M, Sison CE, et al. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry 1996;57:455-459
152. Caspi N, Modai I, Barak P, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 2001;16:111-115
153. Tupin JP. The violent patient: a strategy for management and diagnosis. Hosp Community Psychiatry 1983;34:37-40
154. Lancee WJ, Gallop R, McCay E, et al. The relationship between nurses' limit-setting styles and anger in psychiatric inpatients. Psychiatr Serv 1995;46:609-613
155. Melle I, Friis S, Hauff E, et al. The importance of ward atmosphere in inpatient treatment of schizophrenia on short-term units. Psychiatr Serv 1996;47:721-726
156. Reid WH, Gacono C. Treatment of antisocial personality, psychopathy, and other characterologic antisocial syndromes. Behav Sci Law 2000;18:647-662
157. Linehan MM, Tutek DA, Heard HL, et al. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry 1994;151:1771-1776
158. Moeller FG, Dougherty DM, Barratt ES, et al. The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat 2001;21:193-198
159. Schmitz JM, Stotts AL, Rhoades HM, et al. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001;26:167-180